SEE FAR CBT Intervention for Adults With PTSD

A Clinical Study Evaluating the Effects of a SEE FAR CBT Intervention on Psychological Outcomes in Adults With Posttraumatic Stress Disorder.

This single-arm clinical intervention study evaluates a 12-session SEE FAR CBT intervention for adults aged 18 years and older with posttraumatic stress disorder (PTSD). SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will complete self-report psychological questionnaires at three time points: baseline, after completion of the intervention, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms and related psychological outcomes over the course of treatment and follow-up.

Study Overview

• Status: Recruiting
• Conditions: Post Traumatic Stress Disorder
• Intervention / Treatment: Behavioral: SEE FAR CBT

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Meital Mashash, PhD; Phone Number: 972-50-2888052; Email: meitalm@icspc.org
• Study Contact Backup: Name: Sivan Raz, PhD; Phone Number: 972-54-6634301; Email: sivanra@telhai.ac.il

Study Locations

• Israel
  • Kiryat Shmona, Israel
    • Recruiting
    • Community Stress Prevention Center
    • Contact: Meital Mashash, PhD; Phone Number: 972-50-2888052; Email: meitalm@icspc.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

Participants must meet all of the following criteria:

• Age 18 years or older
• PTSD symptoms, defined as a PCL-5 score of 30 or above
• Able to provide informed consent
• Willing and able to participate in 12 weekly individual therapy sessions and complete study questionnaires at baseline, post-intervention, and 3-month follow-up Exclusion Criteria

Participants will be excluded if they meet any of the following criteria:

• Pregnancy at the time of enrollment, due to the potential influence of pregnancy and childbirth during the treatment or follow-up period on psychological outcomes.
• Currently receiving psychotherapy of any type that began less than 3 months prior to enrolment.
• Initiation of psychiatric medication less than 3 months prior to enrolment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SEE FAR CBT Intervention; Participants in this single-arm study will receive 12 therapeutic sessions of SEE FAR CBT for PTSD, delivered approximately once weekly.	Behavioral: SEE FAR CBT; SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will receive 12 therapeutic sessions delivered approximately once weekly as a structured psychological intervention for PTSD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in PTSD symptoms	PTSD Checklist for DSM-5 (PCL-5). PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.	Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in anxiety symptoms	Generalized Anxiety Disorder-7 (GAD-7). Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.	Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in depressive symptoms	Patient Health Questionnaire-9 (PHQ-9). Depressive symptoms will be assessed using the PHQ-9. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Change in PHQ-9 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.	Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in perceived stress	Perceived Stress Scale (PSS). Perceived stress will be assessed using the PSS. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Change in PSS total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.	Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in resilience	Connor-Davidson Resilience Scale (CD-RISC-10). Resilience will be assessed using the CD-RISC. Total scores range from 0 to 40, with higher scores indicating greater resilience. Change in CD-RISC total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.	Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in somatic symptoms	Patient Health Questionnaire-15 (PHQ-15). Somatic symptoms will be assessed using the PHQ-15. Total scores range from 0 to 30, with higher scores indicating greater somatic symptom severity. Change in PHQ-15 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.	Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in trauma-related use of imagination and coping	Fantastic Reality Ability Measurement (FRAME). Trauma-related use of imagination and coping will be assessed using the FRAME questionnaire. The FRAME is a 21-item measure of fantastic reality ability, defined as the capacity to use imagination in response to stress or trauma. Items are rated on a 1-7 Likert scale, and mean scores range from 1 to 7, with higher scores indicating greater fantastic reality ability. Change in FRAME score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.	Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention

Collaborators and Investigators

• Sponsor: Community Stress Prevention Center
• Investigators: Principal Investigator: Meital Mashash, PhD, Community Stress Prevention Center; Principal Investigator: Sivan Raz, PhD, Tel Hai College

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: July 1, 2026
• First Submitted That Met QC Criteria: July 17, 2026
• First Posted (Actual): July 22, 2026

Study Record Updates

• Last Update Posted (Actual): July 22, 2026
• Last Update Submitted That Met QC Criteria: July 17, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: PTSD; Intervention; SEE FAR CBT
• Additional Relevant MeSH Terms: Trauma and Stressor Related Disorders; Mental Disorders; Stress Disorders, Traumatic; Stress Disorders, Post-Traumatic
• Other Study ID Numbers: SEE-FAR-CBT-PTSD-NORTH-2026

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data will not be shared due to the sensitive clinical nature of the data and participant privacy considerations.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No